lifesciences
Innopsys

Towards high-throughput immunomics for infectious diseases: use of nextgeneration peptide microarrays for rapid discovery and mapping of antigenic determinants

Santiago J Carmona1, Morten Mielsen1,2, Claus Schafer-Nielsen3, Juan Mucci1, Jaime Altcheh4, Virginia Balouz1, Valeria Tekiel1, Alberto C Frasch1, Oscar Campetella1, Carlos A Buscaglia1, and Fernan Agüero1.
1. Instituto de Investigaciones Biotecnologicas – Instituto Tecnologico de Chascomus, Universidade de San Martin – CONICET, Sede San Martin, B 1650 HMP, San Martin, Buenos Aires, Argentina
2. Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, 2800 Lyngby, Denmark
3. Schafer-N AmS, 2100 Conpenhagen, Denmark
4. Servicio de Parasitoligia y Chagas, Hospital de Niños Ricardo Guiterrez, Ciudad de Buenos Aires, Argentina  

Abstract

Complete characterization of antibody specificities associated to natural infections is expected to provide a rich source of serologic biomarkers with potential applications in molecular diagnosis, followup of chemotherapeutic treatments, and prioritization of targets for vaccine development. Here, we developed a highly-multiplexed platform based on next-generation high-density peptide microarrays to map these specificities in Chagas Disease, an exemplar of a human infectious disease caused by the protozoan Trypanosoma cruzi. We designed a high-density peptide microarray containing more than 175,000 overlapping 15mer peptides derived from T. cruzi proteins. Peptides were synthesized in situ on microarray slides, spanning the complete length of 457 parasite proteins with fully overlapped 15mers (1 residue shift). Screening of these slides with antibodies purified from infected patients and healthy donors demonstrated both a high technical reproducibility as well as epitope mapping consistency when compared with earlier low-throughput technologies. Using a conservative signal threshold to classify positive (reactive) peptides we identified 2,031 disease-specific peptides and 97 novel parasite antigens, effectively doubling the number of known antigens and providing a tenfold increase in the number of fine mapped antigenic determinants for this disease. Finally, further analysis of the chip data showed that optimizing the amount of sequence overlap of displayed peptides can increase the protein space covered in a single chip by at least ~3 fold without sacrificing sensitivity. In conclusion, we show the power of high-density peptide chips for the discovery of pathogen-specific linear B-cell epitopes from clinical samples, thus setting the stage for high-throughput biomarker discovery screenings and proteome-wide studies of immune responses against pathogens

SIÈGE SOCIAL

Parc d'activités Activestre
31390 Carbonne - FRANCE

CONTACT

Tél. +33 561 971 974
Fax +33 561 971 975